Floatz logo

Trospium

Manic Bipolar Affective Disorder

Bristol-Myers SquibbSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Manic Bipolar Affective Disorder cohort.

Asset / SponsorPhaseRating
Risperidone
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 4BBB
LITHIUM, ELEMENTAL
University of Cincinnati
Phase 4BBB
QUETIAPINE
University of Cincinnati
Phase 4BBB
Brexpiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3BB
Lamotrigine
Medical University of South Carolina
Phase 4BB

View all 27 →

Same molecule, other indications

Trospium is also rated in:

schizophreniaActive
BBB
Indicative · Phase 4
78 / 100
View asset →
overactive bladderDormant
BB
Indicative · Phase 4
65 / 100
View asset →
cognitive disorderActive
B
Indicative · Phase 3
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →